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ROLE OF MINAR1 IN RENAL CANCER 
EVAN SUTHERLAND 
ABSTRACT 
  Renal cell carcinoma is a high risk and high mortality cancer. While the VHL 
pathway is frequently altered in renal cell carcinoma, emerging evidences points towards 
involvement of multiple complex pathways in the progression of renal cell carcinoma.    
In this present work, we aimed to investigate the role of newly identified protein, 
Major Intrinsically disordered NOTCH2-Associated Receptor 1 (MINAR1), in renal cell 
carcinoma.  
We used immunohistochemistry and demonstrated that MINAR1 is highly 
expressed in normal kidney epithelium. Furthermore, MINAR1 was expressed at variable 
levels in human renal cell carcinoma cell lines. More importantly, we found that 
MINAR1 was significantly downregulated in human samples of renal cell carcinoma.  
Although further studies are needed, our data suggests a potential role for 
MINAR1 in renal biology.  Given that MINAR1 expression appears to be downregulated 
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Epidemiology and Impact of Renal Cancer 
Renal cancer currently ranks 7th in the United States among the top 10 commonly 
diagnosed cancer. Despite reductions in the incidences of other malignancies, renal 
cancer incidence is predicated to increase (Cronin et al., 2018). Renal cancer is typically 
categorized as a high risk and high mortality disease. It is estimated that roughly one fifth 
of the new cases of renal cancer diagnosed in 2016 resulted in death (Siegel R., 2019). 
An estimated 73,820 new cases are expected to be diagnosed in the United States alone 
(Siegel R., 2019). 
Out of all the renal cancers, the most common form is renal cell carcinoma, RCC 
(Eble et al., 2008). RCC is a collection of diseases that arise from the malignancies of the 
nephrons of the kidney (Shuch B., 2015). These carcinomas arise from the renal 
epithelium and are estimated to be roughly 90% of all renal cancer cases. The 
pathological syndromes most commonly associated with RCC include von Hippel-Lindau 
disease, hereditary leiomyomatosis, tuberous sclerosis, hereditary papillary RCC, SDH-
associated RCC, and Birt-Hogg-Dube syndrome (Stratton 2016). 
RCC diseases are typically grouped into less than ten histological and molecular 
subtypes. For the purposes of this introduction, we will focus on biochemical pathways of 
the most common subtype of renal cell carcinoma which is clear cell Renal Cell 
Carcinoma (ccRCC) (Hsieh et al., 2017). Clear cell renal carcinoma is typically identified 
via biopsy through histologic examination and is named after its enlarged and translucent 
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cytoplasm seen under the microscope (Algaba et al., 2011). Prognostic evaluation of 
ccRCC tumors is typically based upon TNM staging and Furhman’s grade. 
 The bodies of ccRCC tumors are highly vascularized. The surface of the tumor 
typically appears yellow due to high amounts of lipids and may also exhibit signs of areas 
of necrosis, known as “pseudo-cysts”. ccRCC cells are thought to originate from the 
proximal tubule portion of the nephron (Prassad et al., 2007). Non-solid forms of clear 
cell renal cell carcinoma are of low malignancy and are classified as multilocular cystic 
RCC (Eble and Bonsib, 1998). These tumors are also noted for having high numbers of 
immune cell infiltrates (Shleypen et al., 2006).  
ccRCC cells most commonly metastasize to the lung, bone, lymph, and liver. 
ccRCC also can metastasize to other organs as it is known for unusual patterns of 
metastasis (Bianchi et al., 2012). While researchers have made attempt to find candidate 
biomarker for diagnosis and prognosis of RCC such as carbonic anhydrase 9 (CA9), 
(Oosterwijk, 2014) microRNAs, (Schlanza, 2017) and others, to date no biomarkers are 
considered robust enough to be regularly used in the clinic as of yet (Soultati 2015). 
 
Clear Cell Renal Cell Carcinoma Biology and Oncogenesis 
 In this section, I will review von Hippel-Lindau (VHL) and oncogenic 
pathways such as the PI3K/AKT/mTOR pathway, as they are considered major cancer 
causing in RCC.  In addition, a summary of the pathways and therapeutics involved in 




It is important to note that sequencing of multiple regions of ccRCC tumors have 
shown a significant amount of intratumor heterogeneity at the genetic, transcriptomic and 
proteomic levels (Gerlinger et al., 2012; Gerlinger et al., 2015).  
With the use of large-scale parallel sequencing, other major defective pathways in 
ccRCC besides VHL and PI3K have been identified (Figure 2).  Most mutations are fairly 
infrequent but three pathways are mutated in over 10% of ccRCC cells sampled: PBRM1, 
BAP1 and SETD2. Similar to VHL, PBRM1, SETD2, and BAP1 are categorized as 
“two-hit” tumor suppressor genes. They also all reside on regions of chromosome 3p  
close to the location of the VHL gene and are involved in chromatin maintenance (Figure 
3) (Brugarolas, 2013; Liao et al., 2015; Turajlik and Larkin, 2015).  
Figure 1: Biochemical pathways involved in ccRCC: Major pathways 




In addition, pathways will low levels of observable mutations have been 
implicated in ccRCC maintenance and development. For example, p53 proteins levels 
have been observed to be frequently elevated in ccRCC tissue although this occurs 
independent of mutations (Chemeris et al., 1995). 
Figure 3: Histone and chromatin modification in ccRCC: Depicted 
above are a number of altered genes which aree involved in chromatin 
maintenance which aree aberrant in ccRCC. Green represents somatic 
mutation while green and orange represent somatic and germline 
mutations 3 (Turajlik and Larkin, 2015). 
 
Figure 2: Somatic mutation frequency in ccRCC: This diagram depicts 
the frequency of mutation within populations of ccRCC cells2 (Turajlik 




Therapeutics for targeting RCC have typically involved strategic anti-
angiogenesis via the VHL or PI3K pathways (Banumathy et al., 2010). In addition, there 
have been new investigations into immuno-therapeutics such as cytotoxic T-lymphocytic 
antigen 4 blockade, and programmed death ligand 1 inhibition (Pal et al., 2012)  
 At the level of the chromosome, ccRCC common abnormalities regularly include 
deletion of chromosome 3p and the VHL gene which is nearly ubiquitous in ccRCC 
samples (Figure 4) (Gerlinger et al., 2014). In roughly 67% of tumor samples, there is a 
gain in chromosome 5q. In roughly 45% of tumor samples, chromosome 14q is lost. 
(Herbers et al.  1997) This confers a loss in the HIF1a and signals a more aggressive 
ccRCC tumor type. (Shen et al. 2011) Additionally, there are gains of chromosomes 7 
and 12, and losses of chromosome 8p, 9 and Y (Thrash-Bingham et al., 1995).  
 
Figure 4: Chromosomal changes and heterogeneity in ccRCC: Listed 
are a number of common chromosomal changes found in ccRCC as well 
as accompanying gene products effected. Depicted in blue on the left are 
fairly ubiquitous changes in ccRCC; Depicted in red on the right are 
changes which typically only involve a subpopulation of cells within a 




Von Hippel-Lindau Pathway 
As mentioned before, the most well characterized genetic determinant in the 
development and maintenance of kidney cancer is the Von Hippel-Lindau gene. This 
gene is linked to the Von Hippel-Lindau (VHL) disease which was first described as a 
hereditary cancer syndrome by Eugen von Hippel (von Hippel, 1904) and then further 
characterized by Avind Lindau. (Lindau, 1927). The VHL disease was first linked to the 
VHL gene in the 1980s and mapped to chromosome 3p25 (Seizinger et al., 1988). 
In addition to renal cell carcinoma, patients with VHL disease frequently risk 
development of retinal angiomas, central nervous system hemangioblastomas, renal cell 
carcinomas, and pheochromocytomas.   
 Patients with Von Hippel Lindau disease typically inherit a mutated VHL gene in 
an autosomal dominant pattern. Those with VHL disease are typically born “+/-”, with 
one activated and one inactivated copy. The disease is a classic oncogenesis model of the 
“two-hit hypothesis” first proposed by Knudson (1971) wherein inactivation of both 
copies of the gene is required for the formation of dysplastic cysts and further progression 
into malignant growth.  
Even for non-hereditary forms of renal cell carcinoma, the VHL gene is critical to 
the development of the tumor. Mutations in the VHL gene or other downstream 
inactivation of VHL pathway acts as a necessary but not sufficient step towards the 
development of renal cell carcinoma. Inactivation of the gene itself does not cause 
malignant tumors but rather pre-malignant cysts (Rankin, 2006). While this gene is 
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critically important, clearly there are other lesser-known mechanics at work during the 
development of ccRCC. 
Early work on the mutation of VHL gene estimated that roughly 70% of renal 
clear cell carcinomas exhibited a bi-allelic mutation (Linehan et al., 2004; Banks et al. 
2006). Later work showed that through either hypermethylation or somatic mutations the 
gene the gene or its product is rendered inactivated in nearly 88.6% of cases (Moore et 
al., 2011). Work by Sato et al. (2013) has demonstrated that in a significant amount of 
renal cell carcinoma cases without otherwise detectable VHL gene inactivation the 
mRNA profiles are consistent with VHL inactivation. 
The product of VHL gene, referred to as pVHL is actually two different proteins 
with molecular weights of approximately 18kDA and 24kDA due to the VHL gene 
containing two start codons. The two protein products are actually functionally similar 
and are thus the two products are typically only referred to in the literature by their 
common name, pVHL (Schoenfeld et al. 1998). 
The function of pVHL is in essence an effort to deal with oxygen and metabolic 
conditions surrounding the cell. pVLH complexes with the proteins CUL2, elongin C, 
elongin B and Rbx1 (Figure 1) (Duan et al., 1995; Kamura et al., 1999). In the presence 
of suitable amounts of oxygen and iron, the pVHL complex utilizes prolyl hydroxylase 
enzymes to bind to the alpha subunit of the heterodimeric transcription factor known as 
hypoxia-inducible factor (HIF) (Tanimoto et al. 2000; Jaakkola et al., 2001). In the 
normoxic state, proline residues of HIF1a are targeted by the pVHL complex for 
polyubiquination. HIFa is subsequently sent to the proteasome. In ccRCC with its 
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defective VHL pathway, HIFa are not targeted for polyubiquination and is thus 
constituently active.   
 HIFa adjust the microenvironment of cells and tumors via transcription co-
activators which together bind to the hypoxia response element (HRE) (Ema et al., 1999; 
Semenza, 2003). The downstream effects of HIFa also shift the tumor cells anaerobic 
glycolysis, also known as the “Warburg effect”. The binding of HIFa to the HRE alters 
the production of vascular endothelia growth factor (VEGF), glucose transporter 1 
(GLUT1), epidermal growth factor (EGF), platelet derived growth factor (PDGF) and 
affects cell activity in a number of ways. For example, HIFa activates VEGF by 
associating with transcriptional coactivator protein (CREB)-binding protein (CBP/p300) 
via its carboxyl-terminal activation domain (CAD) and thus, in VHL-negative ccRCC, 
tumors angiogenesis is enhanced (Arany et al., 1996). HIFa, normally activated in 
hypoxic conditions, is able to operate even in the presence of oxygen in VHL-negative 
tumors and allows greater metabolic activity in tumor microenvironments without 
blunting by pVHL. 
  Additionally, pVHL is known to have other effects independent of HIFa. These 
effects include promotion of ciliogenesis in renal epithelial cells which is noted to be 
stunted in ccRCC (Schraml et al., 2009), supporting RNA polymerase subunit 1 
(Mikhaylova et al., 2008), stabilizing chromosomes (Schraml et al., 2009), and inhibiting 
NF-kB nuclear transcription factors (Yang et al., 2007). 
Advanced clear cell renal cell carcinomas are known to be resistant to tradition 
chemotherapeutics and radiotherapies but knowledge of the VHL pathway has allowed 
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some therapeutic inroads (Motzer, 2011). In 2004, the first pharmaceutical that targeted 
angiogenetic biochemical pathways in cancer, bevacizumab, was approved (Yang et al., 
2003) and later approved for treating renal cell carcinoma. Bevacizumab followed by a 
number of anti-angiogenesis drugs such as sorafenib (Wilhelm et al., 2008), sunitinib 
(Motzer et al., 2007), axitinib (Rixe et al., 2007), cabozantinib, (Yakes et al., 2011) and 
lenvatinib (Boss et al., 2012).  
 
PI3K/AKT/mTOR Pathway  
The phosphatidylinositol 3 kinase (PI3K) pathway is involved in the regulation of 
cell cycle, proliferation, adhesion, nutrient sensing, angiogenesis, motility, and 
intracellular trafficking (Cantley, 2002). It and downstream targets, including AKT, 
phosphatase and tensin homolog (PTEN), and mammalian target of rapamycin (mTOR), 
are frequently abnormal in ccRCC (Guo et al., 2015).   
Under standard physiological conditions, cytokines, hormones, and growth 
factors, such as EGF, insulin-like growth factor, or PDGF, initiate signaling in this 
pathway bind to respective receptor tyrosine kinases (RTK) via the RTK’s extracellular 
region at the N-terminus (Banumathy et al., 2010). Via this ligand-binding event or 
through the actions of Ras and RAB5 via a G-protein coupled receptor,  
P13K is recruited on the cytoplasmic side of the RTK through the subsequent 
autophosphorylation of P13K then phosphorylates the 3-hydroxyl group of 
phosphatidylinositol lipids found in the inner plasma membrane. This phosphorylation 
recruits AKT and PDK which then have a number of downstream targets involved the 
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array of biological processes described above. PTEN acts a tumor suppressor of this 
pathway by inactivating the signaling cascade by inhibiting AKT and regenerating the 
dephosphorylated phosphatidylinositol lipids.  
In ccRCC, this pathway is dysregulated (Figure 1). Researchers found the overall 
genetic alteration rate of this pathway in ccRCC around 27.7% with frequent mutations in 
MTOR, PIK3, PTEN, and AKT (Guo et al., 2015). Considering epigenetic, 
posttranscription and posttranslational dysregulation, aberration in this pathway is higher 
than the genetic mutation rate might suggest. For example, phosphorylation levels of 
AKT and AKT substrates, an indication of PI3K pathway involvement, are high in 
ccRCC relative to other cancer types (Li et al., 2013; Akbani et al., 2014). The 
dysregulation of this pathway can be considered a source of excess lipid and nucleotide 
buildup noted in ccRCC (Porstmann et al., 2008). Additionally, microRNAs which 
regulate the AKT pathway are significantly down-regulated in RCC tissues (Xu et al., 
2014). 
This pathway is involved in crosstalk with the VHL pathway through promotion 
of HIFa expression via mTORC1. HIFa, in turn, regulates ligands of RTKs including 
EGF, PDGF and VEGF. This pathway can be considered a potential positive feedback-
loop for the abnormal expression of HIFa (Bernardi et al., 2006; Toschi et al., 2008) 
Temsirolimus and everolimus, both inhibitors of mTOR, have shown mild success in 
inhibiting ccRCC tumor growth through lower translation of the mRNA that encodes 





While these aforementioned pathways are of clear importance in ccRCC, interest 
in the involvement of the NOTCH signaling pathway within ccRCC has been increasing 
in recent years. (Johansson et al., 2016;) The NOTCH pathway is highly evolutionarily 
conserved, vital for overall development of embryos, and necessary for nephrogenesis 
within the developing kidney (Artavanis-Tsakonas et al., 1999; Chen et al., 2005).  
There are four known members of the mammalian family of NOTCH receptors, 
numbered 1 through 4 (Radtke et al., 2003).  They act as receptors for both Jagged and 
Delta-like ligands which are found on nearby cells. Upon ligand binding, intracellular l- 
secretase assists in cleaving and releasing the intracellular domain of NOTCH (NICD), 
which then enters the nucleus. In the nucleus, NICD converts a transcriptional repressor 
(CBF1/suppressor of hairless/lag-1) into transcriptional coactivators such as hairy and 
enhancer of split (Hes) and hes-related repressor proteins (Kopan et al., 2009).  
Transcription activators release by NOTCH then effect a myriad of biological 
processes. In tumors, that myriad of biological processes includes induction of the 
epithelial-mesenchymal transition (EMT) (Saad et al., 2010; Espinoza and Miele, 2013), 
promotion of angiogenesis (Zeng et al., 2005), shifting the tumor metabolically toward 
the “Warburg effect”, increased resistance to radiotherapeutics (Wang et al., 2010), and 
cancer stem cell (CSCs) survival (Taratek et al., 2010). 
Irregularities in the NOTCH signaling pathway have been noted to play a role in 
oncogenesis in cancers including acute lymphoblastic leukemia (Weng et al., 2004), 
glioma (Purrow et al., 2005), breast cancer (Callahan and Egan, 2004), pancreatic cancer 
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(Miyamoto et al., 2003), melanoma (Balint et al., 2005), and other cancers (Miele et al., 
2006). The NOTCH signaling pathway acts dynamically, as a powerful oncogene in some 
contexts and a tumor suppressor in others (South et al., 2012).  
In terms of ccRCC, the increasing interest in this pathway is deserving. NOTCH-2 
is an important regulator in the cellular biology of the kidney (Cheng, 2007). Notch-2 is 
the primary NOTCH effector of proximal tubule cell differentiation in the nephron, 
which is the hypothesized origin of ccRCC. Defects in NOTCH-2 cause severely 
disordered kidney development (McCright et al., 2001). 
 Furthermore, l-secretase inhibitors which interfere with NICD have shown some 
success in preventing ccRCC tumor growth in xenografted mice (Sjölund et al., 2008). 
Expression of genes involved in NOTCH signaling have shown to have effects on ccRCC 
prognosis including Presenilin 2, ADAM17 and NUMB (Jędroszka et al., 2017). Higher 
expression of the NOTCH ligands, Jagged1 (Wu et al. 2011) and Delta-like4 (Huang et 
al., 2014), is associated with increased ranged of metastatic sites and worse prognosis in 
ccRCC.  
Additionally, the NOTCH signaling pathway is noted to engage in crosstalk with 
the VHL pathway via interactions with HIFa. NOTCH signaling potentiates HIFa 
response to hypoxia via a regulator of EMT named Snail-1 (Sahlgren et al., 2008).  
NOTCH has also been shown to increase the metastatic potential of ccRCC cells (Ai et 





Major Intrinsically-disordered Notch-2 Associated Receptor-1 
  Major Intrinsically-disordered NOTCH-2 Associated Receptor-1 (MINAR1) was 
recently identified to be associated with the NOTCH-2 pathway (Ho et al., 2018). 
MINAR1 is a cell surface protein found throughout the human body, particularly in the 
heart, brain, breast, and kidney and found to be an inhibitor of angiogenesis. MINAR1 is 
composed of 916 amino acids and features a small cytoplasmic domain, a transmembrane 
domain and a large extracellular domain. Formerly known as KIAA1024, is a protein 
with a molecular weight of roughly 100kDa. The MINAR1 protein is evolutionarily 
conserved and found in model organisms such as rodent and xenopus.   
MINAR1’s extracellular domain is notable for its intrinsically-disordered protein 
(IDP) structure which is 70% disordered. It and other IDPs, such as p53, are hypothesized 
to dynamically gain their structure through association with other molecules (Iakoucheva 
et al., 2002).  
Additionally, a decrease in the expression of the protein was shown to correlate 
with more advanced stages of breast cancer; furthermore, its reintroduction into breast 
cancer cell lines was shown to inhibit tumor growth (Ho et al., 2018). More recently, 
another group identified MINAR1 (relabeled UBTOR) as a potential tumor suppressor 








SPECIFIC AIMS AND OBJECTIVES 
The overall goals of this project were to investigate the role of MINAR1 in RCC. 
The specific aims of this project were:  
I: Determine the expression of MINAR1 in normal renal tissue.  
II Determine expression of MINAR1 in human renal cancer cell lines.  





Antibodies Use and Verification 
Rabbit polyclonal anti-MINAR1 antibody was developed in our laboratory and its 
specificity was further validated (Ho et al., 2018). Anti-MINAR1 antibody was used in 
1:2000 dilutions to detect for the presence of MINAR1 in western blot analysis and used 
in 1:1000 dilutions in immunohistochemical analysis. Mouse monoclonal anti-GAPDH 
antibody (1:5000 dilution) was purchased from Santa Cruz Biotechnology.  
RCC tumor samples 
 Previously paraformaldehyde-fixed RCC tumor biopsy samples were generously 
provided by Dr. Joel Henderson (Department of Pathology, Boston University Medical 
Campus).  17 samples were analyzed for MINAR1. 3 samples from RCC patients were 
not included in analysis as they included only tissue adjacent to RCC tumors and not the 
tissue mass itself. The remaining 14 samples were noted to have downregulation of 
MINAR1 within the tumor relative to surrounding tissue. 
 
Immunohistochemistry 
Slides were cut on microtome set to 5 microns. Ribbons of tissue were then place in 
water bath. Ribbon of tissue were separated per slice and then picked up with charged 
slides. Slides were then placed in oven set to 60C. Slides were then hydrated and 
deparaffinized in the following manner: 5 minutes Propar, 5 minutes Propar, 5 minutes 
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Propar, 5 minutes Propar, 2 minutes 100% EtOH, 2 minutes 100% EtOH, 2 minutes 85% 
EtOH, 2 minutes 75% EtOH. Slides were then washed in H20.  
Antigens were then retrieved via use of Decloaking Chamber. Hydrated Slides were 
transferred to Sodium Citrate Buffer (10mM, 0.05% Tween20, pH 6.0). After putting 
~500ml of H20 into Decloaking Chamber, container with Sodium Citrate Buffer and 
slides were placed into Decloaking chamber and cycle was subsequently started.  
Settings were set to: SP1, i.e. 1st temp, set to 125C for 30seconds, SP2 set to 90C for 
10seconds, SP Limit, i.e. amount of allowable temperature variation, set to 10C. Slides 
were then removed from Decloaking chamber after reaching both SP1 and SP2. Slides sit 
in the boats of Sodium Citrate Buffer for 45 minutes to come down to room temperature. 
Slides were washed for 5-10 minutes with 0.05% TBS Tween (1L 1xTBS + 0.5 mL 
Tween).  
Using a PAP pen, a hydrophobic barrier was created around samples. To ensure 
the slides remain hydrated, a thin layer of water was placed at the bottom of the 
specialized slide holder box. Slides were placed above the water and enough peroxidase 
was added on the tissue inside the PAP barrier. Slides were incubated for 10 minutes at 
room temperature. Slides were then washed twice in 0.05% TBS Tween solution for 5 
minutes.  
Protein Block Serum Free from Abcam IHC Kit was added and incubated for 30 
minutes at room temperature. Protein Block was blotted off and Primary antibody diluted 
with Protein block was added overnight at 4C. Slides were washed in TBS Tween 0.05% 
for 5 minutes. Abcam anti-rabbit HRP 1:500 was added and slides were incubated for 30 
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minutes at room temperature in the dark. Slides were then wash thoroughly in TBS 
Tween 0.05% for 5 minutes. DAB chromogen was then added in a 1:50 DAB Chromogen 
to DAB Substrate dropwise to one slide. Slide was placed under a microscope, timed and 
placed into water. Following slides to standardized to this timing. 
Slides were then counterstained in Hematoxylin diluted with water to 1:10 for 45 
seconds. Counterstained slides were then washed in water baths until the water is clear 
after submersion. Slides were dehydrated by soaking in the following solutions: 2 
minutes in 75% EtOH, 2 minutes in 85% EtOH, 2 minutes in 100% EtOH, 2 minutes in 
100% EtOH, 5 minutes in Propar, 5 minutes in Propar, 5 minutes in Propar, 5 minutes in 
Propar. Slides were then left out to dry for 30 minutes. 
Slides were then mounted with cover slips using roughly 1 drop of VectaMount and 
left to dry for one hour. 
 
Western Blot Analysis 
Cells were rinsed twice with H/S (25mM Hepes (pH 7.4)/150mM NaCl) and 
collected in lyse buffer (10mM Tris-HCl, 10% Glycerol, 5 mM EDTA (pH 7.4), 50 mM 
NaCl, 50 mM NaF, 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 20 
mg/ml aprotinin). The resulting solution was centrifuged and supernatant was collected. 
5X Sample Buffer (3.8% Tris-base, 50% glycerol, 5% sodium dodecyl sulphate (SDS), 
5% β-mercaptoethanol, 0.0025% bromophenol blue) was added to whole cell lysates 
before being placed on heat block at 95°C for 5 minutes. Cell lysate samples were 
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resolved on 10 % SDS-polyacrylamide gel electrophoresis (SDS-PAGE) then transferred 
onto polyvinylidene difluoride (PVDF) membranes. Membranes were blocked with blotto 
(2% non-fat dry milk and 0.05% Tween-20 in Western Rinse) for 1 hour on a rocker. 
After washing with Western Rinse for 5 minutes, membranes were incubated with 
primary antibody for 1 hour at room temperature. Following three 10 minutes washes in 
western rinse, membranes were incubated with secondary antibodies for 1 hour. The 



















MINAR1 is expressed in normal kidney epithelial cells 
To investigate expression of MINAR1 in normal renal tissue, we used 
immunohistochemical staining on mice kidney tissue. Our analysis demonstrated that 
MINAR1 was highly expressed in the nephric tubules of the kidney (Figure 5). 
Expression of MINAR1 within cells of the glomerulus was lower than tubule expression. 
.  
Figure 5: Expression of MINAR1 in mouse kidney tissue: 
Immunohistochemical stains of A) renal cortex stained with MINAR1 B) 
renal cortex stained with no primary antibody C) renal medulla stained 
with MINAR1 D) renal medulla stained with no primary antibody 
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Immunohistochemical analysis of MINAR1 expression in ccRCC 
 To address possible function of MINAR1 in human renal cancer, we stained 
tissues from RCC patients (17 cases) for MINAR1.  
Analysis of fourteen eligible samples of RCC demonstrated that expression of 
MINAR1 was noted to be lower in the RCC tissue when compared to surrounding 
adjacent tissue (Figure 6).  
 
 
Figure 6: Expression of MINAR1 in human RCC tissues: Immunohistochemical 
staining of MINAR1 within RCC tissue samples depicted a marked decrease in the 
expression in tumor tissue relative to surrounding tissue 
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Expression of MINAR1 in RCC Cell Lines 
 Next, we examined expression of MINAR1 in several RCC cell lines including, 
786-0, CAKl-1, A948, TKO and several colorectal cancer (CRC) cell lines: RKO, DLD1, 
HT29, and HCT116 via Western blot analysis.  
Among the cell lines tested, 786-0 cells were negative for MINAR1 (Figure 7). 
However, CAKI-1, A498 and TK10 cells were positive for MINAR1.   Similarly, CRC 
cell line, RKO expressed very low level of MINAR1, whereas other cell lines such as 




Figure 7: Expression of MINAR1 and GAPDH in RCC and CRC cell 
lines: Immunoblot of lysed RCC and CRC cell lines probed for MINAR1.  
786-0 cells show little to no expression of MINAR1 while other RCC cell 
lines (CAKl-1, A498, TK10) show expression. RKO cell lines show little 
to no expression of MINAR1 while other CRC have moderate (DLD1) to 





In this study, we identified MINAR1 as a potential regulator in RCC.  
In order to identify the expression of MINAR1 within renal tissue, we conducted 
immunohistochemical studies on mice renal kidney tissue. MINAR1 was found to be 
expressed throughout the tubules of renal tissue.  
Once we were able to verify the protein’s expression in mouse kidney tissue, we 
then explored human tissue samples of RCC.  Overall, expression of MINAR1 in the 
tumor tissue was found to be downregulated when compared to adjacent renal tissue in 14 
of the eligible cases (Figure 6).  
Furthermore, we found 786-0 RCC cell line and the RKO cell line did not express 
MINAR1, while other renal and colorectal cancer cell lines expressed MINAR1 (Figure 
7). 
While we were able to determine MINAR1 expression in RCC, the function of 
MINAR1 within RCC remains unknown. In order to investigate the biological function of 
MINAR1 in RCC, our lab has constructed 786-0 cells expressing MINAR1. 
While further exploration into the function of MINAR1 in RCC is required, 
expression of MINAR1 in RCC suggests a potential function for MINAR1 in the 
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